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Background:  Multidrug  resistant  tuberculosis  (MDR-TB)  poses  serious  challenges  for  tuberculosis  control
in many  settings,  but  trends  of  MDR-TB  have  been  difﬁcult  to measure.
Methods:  We analyzed  surveillance  and  population-representative  survey  data  collected  worldwide  by
the  World  Health  Organization  between  1993  and  2012.  We  examined  setting-speciﬁc  patterns  asso-
ciated  with  linear  trends  in the  estimated  per  capita  rate  of  MDR-TB  among  new  notiﬁed  TB cases  to
generate  hypotheses  about  factors  associated  with  trends  in  the  transmission  of highly  drug  resistant
tuberculosis.
Results:  59  countries  and  39  sub-national  settings  had  at least  three  years  of  data,  but  less than  10%  of
the  population  in the  WHO-designated  27-high  MDR-TB  burden  settings  were  in  areas  with  sufﬁcient
data  to track  trends.  Among  settings  in  which  the  majority  of  MDR-TB  was  autochthonous,  we  found
10  settings  with  statistically  signiﬁcant  linear  trends  in per  capita  rates  of MDR-TB  among  new  notiﬁed
TB  cases.  Five  of these  settings  had  declining  trends  (Estonia,  Latvia,  Macao,  Hong  Kong,  and  Portugal)
ranging  from  decreases  of  3% to  14%  annually,  while  ﬁve  had  increasing  trends  (four  individual  oblasts  of
the Russian  Federation  and  Botswana)  ranging  from  14%  to  20%  annually.  In unadjusted  analysis,  better
surveillance  indicators  and  higher  GDP  per capita  were  associated  with  declining  MDR-TB,  while  a  higher
existing  absolute  burden  of MDR-TB  was  associated  with  an  increasing  trend.
Conclusions:  Only  a small  fraction  of countries  in  which  the  burden  of  MDR-TB  is concentrated  currently
have  sufﬁcient  surveillance  data  to  estimate  trends  in  drug-resistant  TB.  Where  trend  analysis  was  pos-
sible,  smaller  absolute  burdens  of  MDR-TB  and  more  robust  surveillance  systems  were  associated  with
declining  per  capita  rates  of MDR-TB  among  new  notiﬁed  cases.
ublis© 2014  The  Authors.  P
. Introduction
Individuals infected with Mycobacterium tuberculosis resis-
ant to two important ﬁrst-line drugs, isoniazid and rifampin
designated multidrug-resistant tuberculosis, or MDR-TB), have
reatly diminished probability of successful treatment outcomes
ith standard recommended regimens (Espinal et al., 2000).
he acquisition and subsequent transmission of drug-resistant
B is increasingly recognized as a threat to tuberculosis control
∗ Corresponding author at: Yale School of Public Health, Department of Epidemi-
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license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
(Raviglione and Smith, 2007) and MDR-TB is considered among the
major emerging threats (Morens and Fauci, 2013).
Two  decades ago, the World Health Organization (WHO) ini-
tiated the Global Project on Anti-tuberculosis Drug Resistance.
Through the collection of existing surveillance data, coordination
and support of implementing population-representative drug
resistance surveys, and development of a global reference network
of supranational laboratories providing quality control and quality
assurance for in-country drug-susceptibility testing facilities, this
project aimed to document the burden and to assess trends in drug-
resistant tuberculosis over time (Aziz and Wright, 2005). To date,
country-speciﬁc, regionally-, and globally-aggregated estimates of
the burden of drug-resistant tuberculosis have been produced;
these were most recently updated in 2012 (Zignol et al., 2012)
and are now included in yearly Global Tuberculosis Control Reports
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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WHO, 2013). These reports have permitted us to estimate burden
nd to document our collective failure to thus far scale up the avail-
bility of treatment for MDR-TB to meet the magnitude of the need
n countries most affected (Falzon et al., 2013).
One shortcoming of anti-tuberculosis drug resistance surveil-
ance remains the difﬁculty in discerning the trends in the burden
f MDR-TB. The absence of clear evidence of whether the MDR-TB
roblem is getting worse or better over time stems from two  prob-
ems: the dearth of repeat surveys or routine surveillance in most
igh-burden areas (Zignol et al., 2012) and the imprecision of sur-
eys which limit the ability to detect small changes that might be
bserved over several years (Blower et al., 1995).
The last critical analysis of global MDR-TB trend data worldwide,
onducted on data collected through 2007 documented the diver-
ity of trends that have been recorded. The author concluded that,
iven adequate scale up of public health responses, MDR-TB epi-
emics can be controlled with currently available diagnostic tools
nd treatment options (Dye, 2009). Here we use updated data, col-
ated by the WHO  through 2012, to revisit what can be learned from
xisting sources about trends in MDR-TB. We  ask several ques-
ions of practical importance: In which country or sub-national
ettings can we conﬁdently conclude that the incidence of MDR-TB
s increasing or decreasing? Can we identify factors associated with
rends of transmitted MDR-TB? What can the experiences in these
ettings teach us about the potential controllability of MDR-TB in
ther settings?
. Methods
In the following analyses, we focus on trends of estimated per
apita rates of MDR-TB among new notiﬁed TB cases. Individuals
re classiﬁed as new TB cases if they have been exposed to less
han one month of anti-TB therapy in the past, thus drug resistance
mong these cases reﬂects transmitted resistant M.  tuberculosis
WHO, 2009). Accordingly, our analysis of trends of MDR  among
ew TB cases aims to provide insight into whether the spread of
DR-TB is increasing or decreasing over time in a given country or
etting.
.1. Data sources
Our analyses are based on national and sub-national surveil-
ance data submitted to the World Health Organization (WHO)
etween 1993 and 2012. Data are generated from special surveys
f a representative sample of patients with pulmonary TB or con-
inuous surveillance based on routine diagnostic drug susceptibility
esting (DST) of all bacteriologically-conﬁrmed TB patients. A global
etwork of 32 Supranational TB Reference Laboratories controls the
uality of DST results in surveys (van Deun et al., 2011). The number
f new notiﬁed TB cases is reported by year to the WHO  for each
ountry or sub-national area. We  calculated TB notiﬁcation rates
er 100,000 by dividing these notiﬁcation numbers by population
stimates obtained from UN sources (United Nations, 2012).
We present results from all settings that reported estimates of
DR  risk or direct measures of MDR  amongst newly notiﬁed TB
ases in at least two different years. Information on drug resistance
mong notiﬁed cases are derived from two types of sources. In some
ountries, all newly notiﬁed cases receive DST and drug resistance
mong these cases is reported. In the remaining countries, esti-
ates of the risk of drug-resistance among new cases are obtained
hrough population-representative surveys. For these settings, we
stimate the number of MDR-TB cases among new notiﬁed TB cases
y multiplying the risk of MDR  among new TB cases from the
opulation-representative survey by the notiﬁcation numbers for
ew notiﬁed TB cases reported in each year that a survey was done.pdates 17 (2014) 105–123
Over the time period covered by this review, recommended DST
approaches included several based on solid culture (i.e. proportion
method, resistance ratio method, absolute concentration method),
liquid culture (i.e. BACTEC, MGIT), and, in more recent years, molec-
ular tests such as line probe assays (WHO, 2009). Newer molecular
tests such as GeneXpert MTB/RIF have recently been approved, but
no survey or surveillance results based on this test were included
in this time period. While each survey or surveillance data point
was based on DST using one of these recommended approaches,
the DST method was  not uniformly provided to the WHO.
2.2. Trend estimation
We  estimated the average annual percentage changes in the
estimated per-capita rates of MDR-TB among new notiﬁed TB cases
and per-capita rates of new notiﬁed TB cases in each country/sub-
national setting. While we report annual percentage change in
any country with at least two surveys or two years of surveil-
lance, we limited our formal analysis of statistically signiﬁcant
trend to countries with at least three data points. For settings with
data from at least three years, we identiﬁed countries and sub-
national settings with statistically signiﬁcant trends by testing the
null hypothesis of no linear trend (see Appendix for details).
When testing for trends in estimated per capita rate of MDR-
TB among new notiﬁed TB cases, we  weighted the regression by
the number of TB cases that were tested for MDR-TB in the rel-
evant population-representative survey, since larger surveys have
greater precision. When testing for trends in the rate of new TB noti-
ﬁcations, we  weighted the regression by the population size in the
country/sub-national area in each year. For countries reporting no
MDR-TB cases in a given year, we made a small adjustment to allow
us to test for linear trend on the log scale (see Appendix for details).
2.3. Identifying setting-speciﬁc factors associated with trends in
the incidence of new MDR-TB notiﬁcation
For countries and sub-national settings where we  rejected the
null hypothesis of no statistically signiﬁcant linear trend over time
in the estimated per capita rate of MDR-TB among new noti-
ﬁed TB cases, we  explored the association of these trends with
selected demographic, epidemiological, health system and eco-
nomic factors that we a priori considered to be potentially linked
to changes in this rate. These factors included variables related to
TB programs and surveillance capacity (the number of years of
survey/surveillance data, the average TB case detection rate, the
percent of new TB cases receiving drug susceptibility testing), epi-
demiological variables (percent of new TB cases that are MDR,
percent of retreatment TB cases that are MDR, average number
of estimated MDR-TB cases among notiﬁed TB cases, estimated
fraction of MDR-TB cases not treated, average HIV prevalence),
and economic variables (average GDP per capita and average total
health expenditures). We  used descriptive analyses and linear
regression to identify factors that were associated with statisti-
cally signiﬁcant changes in the estimated per capita rate of MDR-TB
among new notiﬁed TB cases. We  present unadjusted results due to
the small number of countries available for inclusion in ﬁnal trend
analyses.
This study was funded by US National Institutes of Health
U54GM088558 (TC), US NIH K01AI102944 (HEJ), and US NIH K01
HD071929-02 (CL). The content is solely the responsibility ofNational Institute of Allergy and Infectious Disease or the Ofﬁce
of the Director, NIH. The funder had no role in the analysis or the
decision to publish this manuscript. USAID was a principal salary
supporter of WHO  staff involved in this Article.
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. Results
Our analysis included a total of 129 settings reporting at least
wo surveys or surveillance covering at least two  years to the
HO between 1993 and 2012; this included 89 countries and 40
ub-national and special administrative settings. The sub-national
ettings included 34 oblasts of the Russian Federation; Barcelona,
pain; Bangui and Bimbo, Central African Republic; Mpumalanga
rovince, South Africa; Henan Province, China and two  additional
pecial administrative regions within China (Macao and Hong
ong).
.1. Data availability
Fig. 1 shows the distribution of numbers of surveys (or years of
urveillance) for each of the settings as well as the geographic distri-
ution of information included in this analysis. We  note that many
dditional settings had submitted data for only one year and these
re not represented in the ﬁgure. In total there were 39 settings
24 country and 15 sub-national) with only two  years of surveil-
ance data and 6 countries with zero notiﬁed MDR-TB cases in each
eporting year (these were excluded from the analysis since these
ata provide no information about trends) leaving 59 countries and
5 sub-national settings available for the trend analysis. Appendix
able A1 shows the number of notiﬁed new cases tested for drug
usceptibility and the number found to be MDR  for each setting and
ear of surveillance or survey.
Thirteen of the 27 WHO-designated “high MDR  burden”
ountries (WHO, 2013) had at least two surveys or years of surveil-
ance data, though several of those with the largest burden only had
epeat surveys at a sub-national level (e.g. China and the Russian
ederation). Of the persons living in these countries, only an esti-
ated 8.3% lived within areas that have been covered by at least
wo surveys or two years of surveillance data.
In unadjusted analyses, we found a statistically signiﬁcant pos-
tive association between the number of years for which a country
rovided data and the GDP per capita; each additional year of
ata was associated with a US$2281 higher GDP per capita (95%
I: US$1440–3123, p < 0.001). We  also found a statistically signiﬁ-
ant negative association between the number of years for which a
ountry provided data and the estimated TB incidence per 100,000
opulation; each additional year of data was associated with 12.2
ewer incident TB cases per 100,000 (95% CI: 19.0–5.3, p < 0.001).
.2. Trend analysis
Following Dye (2009), we plotted the relationship between the
stimated trend in the annual percent change in the per capita rate
f new notiﬁed TB rate and annual percent change in the estimated
er capita rate of MDR-TB among these new TB cases for each set-
ing (Fig. 2). The relationship between the trend in TB and that in
DR-TB is useful because it helps to clarify where the rate of MDR-
B was increasing or decreasing concurrently with TB (upper right
nd lower left quadrants) and where the trends in MDR-TB and TB
ppeared to be diverging (upper left and lower right quadrants).
urthermore, as suggested by Dye and Williams (2009), quantify-
ng the relative trend in MDR-TB versus TB-overall may  provide
nsight into the relative reproductive number of MDR-TB versus
rug-susceptible TB, a key measure that is inﬂuential in projections
f the long-term trajectory of MDR-TB. The reproductive number
s deﬁned as the expected number of secondary cases of disease
ttributable to a single infectious case. Consistent with Dye’s ear-
ier analysis, we found that every possible combination of TB and
DR-TB trend has been observed.
Eighteen settings (12 countries, Hong Kong, Macao, and four
blasts of the Russian Federation) had statistically signiﬁcantpdates 17 (2014) 105–123 107
linear trends in per capita rate of MDR-TB among newly notiﬁed
cases over time. Nine of these settings had signiﬁcant decreases in
MDR-TB over time (Fig. 2, red markers); these decreases ranged
from −3.3% per annum in Estonia to −14.8% per annum in Macao.
Nine had signiﬁcant increases in MDR-TB over time (Fig. 2, green
markers); these increases ranged from 3.6% per annum in the
United Kingdom to 20.7% per annum in Botswana. Thirteen of these
seventeen settings also had statistically signiﬁcant trends in new TB
notiﬁcation (Fig. 3, open markers); the trend in notiﬁed TB was in
the same direction as the trend in the estimated MDR-TB notiﬁca-
tion rate in all but three of these countries (Finland and Austria
where MDR-TB was  increasing while TB was  decreasing, and
Australia where MDR-TB was decreasing while TB was increasing).
3.2.1. Immigration patterns and MDR-TB trends
In eight of the 18 settings with statistically signiﬁcant MDR-TB
trends, the majority of TB cases occurred among the foreign born.
Four of these settings experienced decreasing trends of MDR-TB
(United States of America, Israel, Germany, and Australia), while
four experienced increasing trends (United Kingdom, Sweden,
Finland, and Austria).
In settings in which the foreign born dominate TB epidemiology,
trends in MDR-TB may  reﬂect changes in immigration patterns (e.g.
the numbers and origins of the foreign-born), changes in the type or
effectiveness of screening practices (e.g. pre-arrival screening prac-
tices), and/or changes in the epidemiology of TB in the immigrants
countries of origin. Accordingly, since these trends reﬂect several
factors that may  be extrinsic to the situation within the country
of destination, ascribing trends in MDR-TB to local program per-
formance or to differences in the reproductive number of MDR-TB
may  be misleading.
3.2.2. Trends in countries where MDR-TB trends may reﬂect local
dynamics
The remainder of our analysis is restricted to the 10 settings
where the burden of MDR-TB is not concentrated amongst the
foreign-born. In these settings, changes in MDR-TB over time likely
reﬂect changes in the intrinsic dynamics of drug-resistant TB and
thus may  be useful in identifying local factors associated with these
trends. These included ﬁve settings with declining MDR-TB inci-
dence (Latvia, Estonia, Portugal, and the two  special administrative
regions of China) and ﬁve settings with rising MDR-TB incidence
(Botswana and four oblasts in the Russian Federation).
3.2.2.1. Declining trends of MDR-TB. The clearest success stories of
control of the spread of MDR-TB were found in the Baltic states of
Latvia (between 1996–2012) and Estonia (1998–2012). Consistent
with earlier analyses (Dye, 2009; Blondal et al., 2011), we  found
that Estonia and Latvia reduced the incidence of notiﬁed cases of
transmitted MDR  TB by approximately 3–4% per annum (alongside
slightly faster rates of reduction in non-MDR-TB) (Fig. 3).
The speed of decline in MDR-TB incidence in Hong Kong
(1996–2012), Macao (2005–2012) and Portugal (2000–2011)
exceeded the rates at which non-MDR-TB declined, suggesting that
the effective reproductive number of MDR-TB in these settings may
have been lower than that of non-MDR-TB in these settings (Dye
and Williams, 2009).
3.2.2.2. Rising trends of MDR-TB. The estimated per capita rate
MDR-TB among new notiﬁed cases appeared to be rising over time
in the epidemiologically and geographically disparate settings of
Africa (Botswana) and several oblasts of the Russian Federation.
In the Russian Federation, an area of substantial global interest
because of the historically high prevalence of MDR-TB among
both new and previously treated cases, we  found evidence of ris-
ing rates of MDR-TB among new notiﬁed cases over the study
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Fig. 1. Global map  of drug resistance surveillance data available for trend analysis. Countries and sub-regional settings reporting at least two  years of representative data on
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eriod in four of the 22 oblasts with at least three data points.
he remaining 18 oblasts had no signiﬁcant linear trends (possibly
ue to lack of statistical power or the presence of more compli-
ated non-linear trends (Appendix Fig. A1)) and twelve additional
blasts had only two data points to consider. In the four oblasts
ith increasing per capita rates of MDR-TB, data were available
n Mary-El between 2006 and 2011, in Karelia between 2009 and
011, in Ivanovo between 1998 and 2011, and in Tomsk between
999 and 2011. It is notable that the four oblasts had similar
ates of increase (ranging from 14.0% to 19.2% per annum). It is
mportant to note that in Tomsk, where we found a statistically
igniﬁcant increasing linear trend between 1999 and 2011, visual
nspection of the data series suggests that this estimated rate of
DR-TB may  actually have begun to decline beginning around
005. We reﬂect on potential drivers of this pattern further in
ection 4.
In Botswana, the sole African setting in our analysis with three or
ore data points, the estimated per capita rate of MDR-TB among
ew notiﬁed cases was rising more than 20% per annum between
996 and 2008, while new TB notiﬁcation rates overall appeared to
e relatively stable.
In each of these settings, the rate at which the MDR-TB was
ncreasing exceeded the rate at which TB overall was  increasing,
onsistent with a higher relative effective reproductive number of
DR-TB.
.2.2.3. Other countries of note without statistically signiﬁcant trends.
hile we restricted our formal analysis to countries with statisti-
ally signiﬁcant linear trends, we elected to also highlight trends in
eru and the Republic of Korea, two countries that had increasing
DR-TB trends in previous analyses (Zignol et al., 2012; Dye, 2009).
ased on updated data, including new 2012 surveillance data from
eru and revised TB notiﬁcation data from the Republic of Korea,
e found that these countries no longer had statistically signiﬁcant
ncreasing linear trends our estimate of MDR-TB (Appendix Fig. A2).
e offer additional thoughts about the situation in these countries
n Section 4.ing at least two  years of data, there is an inverse relationship between estimate TB
3.2.3. Factors associated with trends
We list several demographic, epidemiological, health systems,
and economic variables that we a priori considered might be associ-
ated with trends in the incidence of transmitted MDR-TB (Table 1).
Given the limited number of countries in which signiﬁcant lin-
ear trends reﬂected dynamics intrinsic to that country, we present
unadjusted linear regression as a means to generate hypotheses
about which factors were potentially related to effective control of
transmitted MDR-TB (Table 2).
We  found that the following factors had statistically signiﬁcant
associations with trends in the estimated per capita rate of notiﬁed
new MDR-TB: the number of years for which a country had survey
or surveillance data, the estimated fraction of active TB cases that
were detected, the estimated burden of new MDR-TB cases (i.e. the
estimated number of MDR-TB cases among notiﬁed TB cases), and
the per capita GDP. Better surveillance (more years with survey
data and higher case detection rates) and higher GDP  per capita
were associated with improving MDR-TB trends among new cases
while a higher existing absolute burden of MDR-TB was  associated
with a worsening trend.
4. Discussion
This analysis provides an update of country and sub-national
trends of estimated per capita rates of MDR-TB among new notiﬁed
TB cases and offers an assessment of what may  be learned from
settings that have been able to reverse rising rates of MDR-TB.
In contrast to earlier approaches for documenting and under-
standing trends in MDR-TB (Dye, 2009), we  separated out countries
in which the majority of TB (and MDR-TB) occurs among immi-
grants, since these trends may  be related to factors other than
local transmission of MDR-TB. The separate consideration of these
countries is not intended to diminish the importance of interna-
tional migration to MDR-TB trends. Indeed, previous analyses have
demonstrated the importance of migration in the dissemination
of MDR-TB (Falzon and Ait-Belghiti, 2007; Devaux et al., 2009).
It is possible that transnational dissemination of MDR-TB may be
T. Cohen et al. / Drug Resistance Updates 17 (2014) 105–123 109
Fig. 2. Associations between changes in per capita new TB notiﬁcation rate and estimated per capita MDR-TB rate among new cases for countries with at least two years
of  data. The graphs show the estimated annual percent change in the per capita rate of new notiﬁed TB (x-axis) against the annual percent change in the estimated per
capita  rate of MDR-TB among notiﬁed new TB cases (y-axis). The graph on the right is provided to allow for better visualization of the points closest to the origin. The green
markers depict settings with statistically signiﬁcant decreasing trend of MDR-TB, the red markers depict settings with statistically signiﬁcant increasing trend of MDR-TB,
and  the yellow markers depict settings with no statistically signiﬁcant trend of MDR-TB. The black markers depict settings with only two data points for which no formal
trend  analysis was  conducted. (For interpretation of reference to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. Settings with statistically signiﬁcant linear trends in estimated per capita rates of MDR-TB among notiﬁed new TB cases. Each panel displays the time trend for settings
w ng new
s  conﬁ
n nds w
i
e
w
tith  a statistically signiﬁcant linear trend in estimated incidence of MDR-TB amo
how  MDR-TB data from surveillance while the gray solid markers and associated
otiﬁcation data. Points are only connected where statistically signiﬁcant linear tre
mportant in other settings as well, for example, by migrant work-
rs in sub-Saharan Africa (Satti et al., 2008).
We  found that stronger surveillance systems were associated
ith a downward trend in MDR-TB (Table 2). Both the capacity
o do routine surveillance (i.e. testing all new TB cases for drugly notiﬁed TB cases. The black solid markers and associated conﬁdence intervals
dence intervals show MDR-TB data from surveys. The open circles show new TB
ere detected.
susceptibility) and, in the absence of surveillance, the ability to do
multiple surveys, was associated with declining MDR-TB among
new TB cases. In Latvia and Estonia, two  clear examples of countries
that have reversed rising epidemics of MDR-TB, the ability to offer
DST routinely to all new cases, is a key element of MDR-TB control
T. Cohen et al. / Drug Resistance Updates 17 (2014) 105–123 111
Table  1
Selected data from settings with statistically signiﬁcant linear trends in estimated per capita rates of MDR-TB among new notiﬁed TB cases.
MDR-TB trend
(annual %
change)a
Number of
years of datab
Type of data Averagec TB case
detection rate (%)
(WHO, 2014a)
Percent of new TB
cases receiving DST
(%) (WHO, 2014b)
Percent of new TB
cases that are MDR
(%) (WHO, 2014b)
Percent of retreatment
TB cases that are MDR
(%) (WHO, 2014b)
Botswana 20.71 4 Survey 60 9 9.6 25.1
Mary  El (Russian Fed) 19.18 5 Surveillance
70
42
16.6 40.6
Karelia (Russian Fed) 16.05 3 Surveillance 57
Ivanovo (Russian Fed) 15.79 7 Surveillance 58
Tomsk Russian Fed) 14.05 11 Surveillance 72
Estonia −3.34 16 Surveillance 87 70 16.0 45.7
Latvia −4.32 16 Surveillance 79 72 10.5 31.9
Portugal −8.50 13 Surveillance 87 38 1.4 6.6
Hong  Kong −8.52 13 Surveillance 87 53 0.9 6.6
Macao −14.81 8 Surveillance 89 74 1.9 5.2
Averagec number
of estimated
MDR-TB among
notiﬁed TB cases
(WHO, 2014b)
Estimated gap in MDR-TB
treatment (% of estimated
cases not treated) (WHO,
2014b)
Averagec annual
estimated TB
incidence (per
100,000) (WHO,
2014a)
Averagec HIV
prevalence (%)
(UNAIDS, 2014)
Averagec
population size
(United
Nations, 2012)
Averagec GDP
per capita
(US$) (World
Bank)
Averagec total
health expenditure
per capita (US$)
(WHO,  2014c)
Botswana 823 61 820 24.8 1,778,702 3869 188
Mary El (Russian Fed)
n/a 59 123 0.6
702,283
5412 309
Karelia (Russian Fed) 685,388
Ivanovo (Russian Fed) 1,144,743
Tomsk Russian Fed) 1,002,691
Estonia 72 23 45 0.9 1,354,230 10,021 567
Latvia 134 11 84 0.5 2,320,459 7613 1710
Portugal 45 51 102 0.7 10,541,469 18,150 1835
Hong  Kong 6 54 76 n/a 6,756,500 27,799 n/a
Macao 46 0 37 n/a 518,487 42,039 n/a
a Calculated in current analysis.
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a DOTS program that had been driving down the incidence of TB,
the per capita rate of MDR-TB among new notiﬁed TB cases contin-
ued to rise over time with a statistically signiﬁcant upward trend
of approximately 4% per annum prior to the addition of 2012 data.
Table 2
Variables associated with trend in estimated per capita MDR-TB rates among new
notiﬁed TB cases. All variables in Table 1 were tested, only those with statistically
signiﬁcant univariable associations are reported here.
% annual change in estimated new
notiﬁed MDR-TB cases
(95% CI)
Surveillance variables
Number of years of data (per year
additional data)
−1.95 (−3.60, −0.30)
Average TB case detection rate (per
1% increase)
−1.20 (−1.70, −0.71)
Epidemiological variables
Estimated number of MDR-TB 3.83 (2.56, 5.10)b See Appendix Table A1 for data from all settings.
c Averages are calculated over years for which MDR  trend data were available for
Blondal et al., 2011; Leimane et al., 2010; ECDC, 2013). These Baltic
ountries also share an aggressive approach to MDR-TB care, with
ndividualized regimens based on DST results and high and increas-
ng rates of MDR-TB treatment success over time. We  note that
hese countries never had very large absolute burdens of MDR-TB,
 factor that we found associated with potential controllability of
DR-TB. These countries have relatively low HIV co-infection rates
though this has been rising in Estonia) which likely contributes to
he high MDR-TB treatment success rates and possibly to the abil-
ty to reverse the upward trend in the estimated rate of MDR-TB
mong new notiﬁed TB. While Tomsk oblast had a rising linear trend
n estimated per capita MDR-TB among new notiﬁed TB over the
nalysis period, this trend may  have been reversing in recent years
Fig. 3). In Tomsk, as in Estonia and Latvia, all new patients receive
ST, thus allowing patients to access MDR-TB treatment before fail-
ng a course of ﬁrst-line treatment. Estonia, Latvia, and Tomsk also
hare a substantial history of strong political commitment toward
ddressing the threat of MDR-TB and partnership between national
B programs and established links with the Green Light Committee
GLC), which facilitated access to quality assured second-line drugs
t reduced prices. Of note, in none of these settings is access to TB
are and treatment for MDR-TB widely available through private
ector providers (Nathanson et al., 2006).
The situations in Estonia, Latvia (and even Tomsk) provide
mportant reassurance even in places where the prevalence of
DR-TB among new cases is very high, MDR-TB epidemics may  be
eversible within the context of highly organized programs that (1)
ggressively identify MDR-TB cases through routine testing of all TB
uspects, even those that have never previously been treated for TB
nd (2) deliver individualized quality-assured MDR-TB treatment
onsistent with DOTS-plus guidelines. Based on the experiences
f these settings, which are more fully described in other publi-
ations (Furin et al., 2011), we would anticipate that if Tomsk can
aintain its current efforts, and if the other Russian oblasts can setting.
implement similar systems of surveillance and treatment, that the
incidence of new MDR-TB in these settings could begin to decline.
Additionally, as stronger economic conditions were associated with
decreasing trends in MDR-TB (as measured by per capita GDP) in
settings included in our analysis, it is possible that more favor-
able economic conditions will be associated with better control of
MDR-TB in other settings.
Is there anything to be learned from the experience in Peru?
As with Estonia, Latvia, and Tomsk, Peru is a setting in which
MDR-TB was  aggressively addressed by partnerships between the
national TB program, a well-established non-governmental organi-
zation with strong capacity to treat MDR-TB, and the GLC. Despitecases among notiﬁed TB cases (per
100 additional cases)
Economic variables
GDP per capita (per $1000
increase)
−0.76 (−1.51, −0.01)
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hat might explain the difference in outcomes between Peru and
hese other countries? While we cannot draw deﬁnitive conclu-
ions, we note that in Peru, because of limited laboratory capacity,
ST was reserved for individuals returning for retreatment and
ndividuals otherwise considered at high risk of MDR-TB or death
e.g. household contacts of MDR  cases and HIV co-infected cases).
ccordingly, individuals with MDR-TB may  have cycled through
everal courses of treatment (during which they may  have ampli-
ed their resistance (Han et al., 2005)), prior to receiving an MDR-TB
iagnosis and being placed on appropriate therapy. These delays
n diagnosis of MDR-TB may  contribute to prolonged infectious-
ess and thus a relatively high effective reproductive number of
DR-TB in this setting (Cohen et al., 2009). We  note expanded
fforts to provide early access to DST, originally included within the
eruvian technical guidelines in 2006 (Ministerio de Salud, 2006)
nd most recently codiﬁed as policy for universal access to rapid
re-treatment tests for resistance for all TB patients in 2013
Ministerio de Salud, 2013), was associated in time with declining
er capita rate of MDR-TB among new TB cases.
In previous analyses, the Republic of Korea has had a statisti-
ally signiﬁcant rising trend in MDR-TB (Zignol et al., 2012; Dye,
009). Here, based on recent modiﬁcations to TB case notiﬁcations
ating back to 1999 (WHO, 2014a), we no longer ﬁnd a statisti-
ally signiﬁcant increasing trend, though the best ﬁt line remains
onsistent with an annual increase of >4% per annum (Appendix
ig. A2). While we have not included this country in our group with
ncreasing MDR-TB, we believe that the situation in the Republic of
orea warrants additional discussion. As described by Seung et al.,
n the Republic of Korea, the National Tuberculosis Program’s role
s largely restricted to the treatment of new TB cases, while a large
rivate sector is responsible for patients returning for retreatment
Seung et al., 2003). Over the past few years, the relative impor-
ance of the private sector appears to be growing, with recent
stimates that 70% of treatment offered in the private sector (Bai
t al., 2007). This is concerning given the historically high rates of
oor treatment outcome and default associated with care delivered
y private sector providers (Hong et al., 1999). As was  previously
he case in Peru, new cases of TB diagnosed in the public sector
o not receive DST in the Republic of Korea. Accordingly, individ-
als with transmitted MDR-TB may  need to cycle through failed
reatment before receiving proper diagnosis and care, resulting
n higher morbidity and mortality and increased opportunity for
nward transmission of MDR-TB. Future studies that measure the
revalence of drug resistance among TB cases treated in the private
ector would provide valuable information in settings where large
ractions of patients seek care outside of the national tuberculosis
rogram (Cohen et al., 2010).
Another potentially important difference between Peru and the
epublic of Korea compared to Estonia, Latvia, and Tomsk is the bur-
en and risk of MDR  that these countries/settings must be equipped
o address. While the average risk of MDR  among new TB patients
s relatively low in Peru and the Republic of Korea, the average esti-
ated annual number of new MDR-TB cases is far higher in these
ountries than it is in Latvia, Estonia or Tomsk (Table 2). This means
hat Peru and the Republic of Korea must maintain systems for ade-
uately diagnosing and treating MDR  among a far larger cohort of
atients which could prove a more difﬁcult task than dealing with a
maller and more highly prevalent condition in parts of the former
oviet Union. The low pre-test probability of MDR-TB among new
ases complicates the diagnosis of drug resistance (as the positive
redictive value of even sensitive and speciﬁc tests for resistance
ay  be compromised) and these tests will need to be delivered to
ery large numbers of new cases with important implications for
he affordability of such approaches.
Botswana is the sole country in Africa with sufﬁcient data to esti-
ate an MDR-TB trend. It is worrisome that in this setting of highpdates 17 (2014) 105–123
HIV prevalence, we observed increasing rates of MDR-TB over time
while the incidence of TB overall appeared stable. While the infor-
mation is too limited to attribute these trends to speciﬁc causes or
to understand how HIV may  or may  not impact the controllability of
MDR-TB epidemics, this pattern suggests that in this setting MDR-
TB had a higher relative reproductive number than TB. The lack
of sufﬁcient data from other African settings is particularly vexing
given the recent documentation of outbreaks of XDR-TB in South
Africa (Gandhi et al., 2006) and the very high prevalence of MDR-TB
found in most recently in Swaziland (Sanchez-Padilla et al., 2012)
(see point 104 in Fig. 2). A planned national drug resistance survey
in South Africa will provide much needed information to better
understand the threat of the spread of MDR-TB in areas where HIV
is highly prevalent.
The majority of countries and settings included in this analysis
did not have statistically signiﬁcant linear changes in the estimated
per capita rates of MDR-TB among new notiﬁed TB cases over time.
This was  due to stability of the estimated per capita rate of MDR-TB,
a lack of sufﬁcient number of repeat samples or large enough stud-
ies to detect trends that might have been present, or the presence
of more complicated time trends in disease burden. In Appendix
Fig. A1 we present the time trends in estimated per capita inci-
dence of MDR-TB among new notiﬁed TB cases for all countries
and settings included in our analyses.
Our analysis of trends in the incidence of new notiﬁed MDR-
TB highlights several issues related to assessing trends in MDR-TB.
First, as clearly shown in Fig. 1, the data available are from a sub-
set of countries and these data cannot be readily used to estimate
global trends. In general, countries with more resources relative to
TB burden are more likely to be included in the analysis. In many
settings, we  currently lack sufﬁciently robust capacity for either
the systematic testing of resistance among all new TB cases or the
capacity to do intermittent population-representative surveys of
drug resistance among new cases. This is particularly evident in
Africa and much of Asia, including India, which is not yet repre-
sented in this dataset for lack of sufﬁcient numbers of repeat drug
resistance surveys at either national or sub-national levels. While
several settings in China have repeat surveys or surveillance data,
and decreasing MDR-TB trends were detected in Macao and Hong
Kong, recent national survey data suggest a serious problem with
MDR-TB in the country with 5.7% of new TB cases infected with
MDR-TB (Zhao et al., 2012). At this time, less than 10% of the popula-
tions within the 27 designated high-MDR-TB burden countries are
reﬂected in this analysis. Of China, India, and Russia, only China is
currently performing nationwide repeat survey of drug resistance.
Given the strong association between strong surveillance systems
and declining MDR-TB trends among countries with adequate data
for trend analysis, the inability to assess the burden of drug resis-
tance over time bodes poorly for countries with weak surveillance
systems.
Second, the data upon which our analyses are based are imper-
fect. We have analyzed trends in estimated per capita rate of
new notiﬁed MDR-TB cases. If surveillance systems have changed
over time, trends in notiﬁcations may  reﬂect these administrative
changes rather than true epidemiological shifts. The variable tim-
ing between M. tuberculosis transmission events and progression
to clinical disease also makes it more difﬁcult to clearly link factors
with trends, but the relatively high risk of progression soon after
infection allays some of this concern (Vynnycky and Fine, 1997).
Furthermore, we have performed aggregated analyses at the level
of country or sub-national region, but there is substantial local het-
erogeneity in the burden of TB (Dowdy et al., 2012) and MDR-TB
(Jenkins et al., 2013; Lin et al., 2012; Manjourides et al., 2012;
Hedt et al., 2012). Surveys in such countries may  either under-
estimate or overestimate resistance, depending on which study
sites contribute to the study (Cohen et al., 2008) and assessing
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hese aggregated trends may  smooth over important local differ-
nces in disease trajectory. Additionally, we have used a simple
pproach for detecting linear trends in the percentage change in
stimated new MDR-TB among notiﬁed TB cases. The selection
f this approach was motivated by the limited data available for
etecting more complex trends, but this approach can fail to detect
mportant changes in disease burden over time. This is best illus-
rated by the analysis in Tomsk, which led us to include it as a
ocation with increasing MDR-TB, when visual analysis suggests
hat after a period of early worsening of the epidemic, the situa-
ion appears to be improving. Given what has been documented
bout the interventions that have been deployed in this oblast
Furin et al., 2011), the timing of this reversal is quite credible. Non-
inear patterns in MDR-TB trends may  be present in other settings
s well (Appendix Fig. A1), though the limited sample sizes and
ide conﬁdence intervals are obstacles for the rigorous detection
f these patterns. Fourth, the drugs to which resistance were tested
nd reported was limited; in particular, we have no reliable mea-
ures of trends in XDR-TB over time since testing for resistance to
uoroquinolone and injectable antibiotics is currently more chal-
enging and less reproducible than for isoniazid and rifampicin.
ifth, given the limited number of settings in which we  detected
rends, our analysis of factors that are associated with these trends
as limited. We  used publically available data to test for unad-
usted associations with trend. Accordingly, we have characterized
hese associations as hypothesis generating and anticipate that this
nalysis can be improved as more data become available in the
uture.
These limitations notwithstanding, our analyses provide both
uarded optimism and reason to be concerned about our ability to
itigate the spread of MDR-TB. The good news ﬁrst: the spread of
DR-TB appears controllable in countries that have made substan-
ial investments in surveillance and response. In particular, based
n the ﬁndings in Estonia and Latvia, it appears that universal DST
or all TB patients and individualized second-line treatment regi-
ens for MDR-TB cases may  be needed to control the transmission
f MDR-TB in areas where the risk of transmitted resistance is
lready very high. The limited data do not yet clarify whether these
easures are sufﬁcient, but we believe they are likely to be a nec-
ssary condition to curb the growth of MDR-TB in other settings.
igher GDP was also associated with declining MDR  in the sett-
ngs included in our analysis. We caution that our analysis should
ot be used to assign causality to factors we found to be associ-
ted with controllability of transmitted MDR-TB, but do suggest
hat increasing investment in surveillance systems (including lab-
ratory infrastructure to conduct DST) and improving treatment
apacity for MDR-TB (Falzon et al., 2013) may  be necessary to suc-
essfully mitigate the spread of MDR-TB. The introduction of rapid,
ore easily scalable technologies for rapid DST, such as GeneX-
ert MTB/RIF (Boeheme et al., 2010), may  facilitate such responses.
he more concerning news: at present, we do not have evidence of
uccessful control of the spread of MDR-TB in areas of high HIV co-
nfection (e.g. Botswana), areas where drug susceptibility testing is
eserved for those failing one (or multiple courses) of standardized
reatment, or in areas where the private sector plays an important
ole in TB treatment. These ﬁndings should provide strong sup-
ort for efforts to improve the strength of surveillance systems and
he vigor of the response to MDR-TB, especially in countries withpdates 17 (2014) 105–123 113
the highest absolute burden of disease including China, India and
Russia.
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Appendix A.
Since incidence rates changing at a constant percentage every
year change linearly on a log scale, we modeled the natural log-
arithm of the TB and MDR-TB incidence rates as the dependent
variable with year as the explanatory variable:
ln(Ry) = b0 + b1y (1)
where ln is the natural logarithm and Ry is the TB (or MDR-TB)
incidence per 100,000 in year y.
The annual percentage change in TB (or MDR-TB) incidence from
year y to year y + 1 = [(Ry+1 – Ry)/Ry] × 100.
Substituting in (1), the annual percentage change in TB or (MDR-
TB) incidence =
exp(b0 + b1(y + 1)) − exp(b0 + b1y)
exp(b0 + b1y)
× 100 = (exp(b1) − 1) × 100
(2)
We ﬁtted the regression line (1) to estimate b1 for TB and MDR-
TB incidence among newly notiﬁed cases in each country and sub-
national area separately.
When modeling TB incidence, we weighted the regression by the
population size in the country/sub-national area in each year. When
modeling MDR-TB incidence, we weighted the regression by the
number of TB cases that were tested for MDR-TB in the population-
representative survey that was  used, since larger surveys will have
higher precision.
To identify countries or sub-national areas with statistically sig-
niﬁcant increasing or decreasing trends in TB or MDR-TB incidence,
we assessed the statistical signiﬁcance of b1 at p < 0.05. We  note that
in some low very low TB burden countries, the estimated number
of MDR-TB cases in some years was zero. Since the logarithm of
zero does not exist, in these cases we added 0.5 to the number of
individuals tested positive for MDR-TB for all datapoints in that
country’s survey or surveillance data (0.5 was chosen to avoid bias
as per Cox (1955)).
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Fig. A1. Time series of estimated per capita rates of MDR-TB among notiﬁed new TB cases for each country with at least 3 data points. Sequential panels depict the rates by
WHO  region (or sub-region): (a) Africa, Eastern Mediterranean, and South East Asia; (b) Americas; (c) Europe, Central; (d) Europe, Eastern; (e) Europe, Western; (f) Western
Paciﬁc.
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Fig. A1. (Continued )
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Table  A1
Sizes of surveys and number of isolates that were found to be MDR  for all settings
included in this analysis.
Country Year Tested num Mdr  num
Australia 2010 868 21
Australia 2011 652 14
Australia 2012 861 16
Albania 2010 186 1
Albania 2011 194 2
Albania 2012 172 1
Algeria 1988 243 3
Algeria 2002 574 8
Andorra 1999 6 0
Andorra 2000 4 0
Andorra 2003 2 0
Andorra 2004 5 0
Andorra 2005 9 0
Andorra 2006 8 0
Andorra 2007 3 0
Andorra 2008 3 0
Andorra 2009 2 0
Andorra 2010 4 0
Andorra 2011 1 0
Argentina 1999 679 12
Argentina 2005 683 15
Austria 1999 703 2
Austria 2000 694 3
Austria 2001 589 4
Austria 2002 633 2
Austria 2003 554 8
Austria 2004 600 17
Austria 2005 570 11
Austria 2006 500 8
Austria 2007 481 8
Austria 2008 439 11
Austria 2009 265 5
Austria 2010 203 5
Austria 2011 257 9
Bahamas 2010 21 0
Bahamas 2011 31 1
Bahamas 2012 27 1
Bahrain 2010 162 0
Bahrain 2011 154 9
Bahrain 2012 160 3
Belarus 2010 1972 507
Belarus 2011 934 302
Belarus 2012 2164 753
Belgium 2000 562 7
Belgium 2001 562 13
Belgium 2002 629 15
Belgium 2003 510 3
Belgium 2004 622 3
Belgium 2005 588 7
Belgium 2006 606 8
Belgium 2007 707 10
Belgium 2008 630 15
Belgium 2009 621 4
Belgium 2010 466 7
Belgium 2011 524 7
Benin 1997 333 1
Benin 2010 403 2
Bermuda 2010 1 0
Bermuda 2011 1 0
Bermuda 2012 2 0
Bosnia and
Herzegovina
1999 1154 3
Bosnia and
Herzegovina
2000 993 1
Bosnia and
Herzegovina
2001 1132 0
Bosnia and
Herzegovina
2002 933 2
Bosnia and
Herzegovina
2003 951 1
Bosnia and
Herzegovina
2004 1048 4
Bosnia and
Herzegovina
2005 1035 4
Table A1 (Continued )
Country Year Tested num Mdr num
Bosnia and
Herzegovina
2006 993 3
Bosnia and
Herzegovina
2007 1267 3
Bosnia and
Herzegovina
2009 854 0
Bosnia and
Herzegovina
2010 600 1
Bosnia and
Herzegovina
2011 704 1
Botswana 1996 407 1
Botswana 1999 638 3
Botswana 2002 1182 10
Botswana 2008 924 23
Brunei Darussalam 2009 164 0
Brunei Darussalam 2010 181 0
Brunei Darussalam 2011 205 0
Brunei Darussalam 2012 166 0
Bulgaria 2010 801 16
Bulgaria 2012 687 16
Cambodia 2001 638 0
Cambodia 2007 781 11
Canada 1994 1325 10
Canada 1995 1242 8
Canada 1996 1203 9
Canada 1997 1366 12
Canada 1998 1206 7
Canada 1999 1268 7
Canada 2000 1162 7
Canada 2001 1262 9
Canada 2002 1172 12
Canada 2003 1153 6
Canada 2004 1154 5
Canada 2005 1130 8
Canada 2006 1058 8
Canada 2007 1113 7
Canada 2008 1098 9
Canada 2009 1321 13
Canada 2010 987 15
Cayman Islands 2011 1 0
Cayman Islands 2012 5 0
Central African
Republic, Bangui and
Bimbo
1998 464 5
Central African
Republic, Bangui and
Bimbo
2009 225 1
Chile 1997 732 3
Chile 2001 867 6
China, Henan Province 1996 646 70
China, Henan Province 2001 1222 95
China, Hong Kong SAR 1996 4424 62
China, Hong Kong SAR 1997 3432 39
China, Hong Kong SAR 1998 3753 49
China, Hong Kong SAR 1999 3460 35
China, Hong Kong SAR 2000 3479 37
China, Hong Kong SAR 2001 3470 27
China, Hong Kong SAR 2004 2682 13
China, Hong Kong SAR 2005 3271 28
China, Hong Kong SAR 2007 2593 8
China, Hong Kong SAR 2008 2443 8
China, Hong Kong SAR 2009 2056 15
China, Hong Kong SAR 2011 1992 17
China, Hong Kong SAR 2012 2061 20
China, Macao SAR 2005 265 6
China, Macao SAR 2006 251 7
China, Macao SAR 2007 251 4
China, Macao SAR 2008 243 5
China, Macao SAR 2009 201 3
China, Macao SAR 2010 221 4
China, Macao SAR 2011 258 4
China, Macao SAR 2012 261 2
Colombia 2000 1087 16
Colombia 2005 925 22
Costa Rica 2006 263 4
Costa Rica 2012 273 0
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Table  A1 (Continued )
Country Year Tested num Mdr num
Cote dIvoire 1996 320 17
Cote dIvoire 2006 320 8
Croatia 1999 761 2
Croatia 2000 780 1
Croatia 2001 713 2
Croatia 2002 747 4
Croatia 2003 732 4
Croatia 2004 669 3
Croatia 2005 586 3
Croatia 2006 614 1
Croatia 2011 353 1
Cuba 1995 337 1
Cuba 1996 426 4
Cuba 1997 241 0
Cuba 1998 284 0
Cuba 1999 321 3
Cuba 2000 377 1
Cuba 2002 195 1
Cuba 2003 193 1
Cuba 2004 177 0
Cuba 2005 169 0
Cuba 2011 313 3
Cuba 2012 269 2
Curacao 2010 5 0
Curacao 2011 1 0
Curacao 2012 1 0
Cyprus 2004 15 0
Cyprus 2005 16 1
Cyprus 2006 22 0
Cyprus 2007 28 2
Cyprus 2008 29 0
Cyprus 2009 27 4
Cyprus 2010 14 0
Cyprus 2011 25 1
Czech Republic 1995 199 2
Czech Republic 1999 628 2
Czech Republic 2000 616 7
Czech Republic 2001 663 8
Czech Republic 2002 488 9
Czech Republic 2003 610 1
Czech Republic 2004 480 4
Czech Republic 2005 562 7
Czech Republic 2006 552 6
Czech Republic 2007 487 8
Czech Republic 2008 483 10
Czech Republic 2009 413 5
Czech Republic 2010 352 7
Czech Republic 2011 392 6
Denmark 1998 412 2
Denmark 1999 392 0
Denmark 2000 392 1
Denmark 2001 356 0
Denmark 2002 273 1
Denmark 2003 283 0
Denmark 2004 267 0
Denmark 2005 307 5
Denmark 2006 286 3
Denmark 2007 269 2
Denmark 2008 253 0
Denmark 2009 209 1
Denmark 2010 209 1
Denmark 2011 257 3
Egypt 2002 632 14
Egypt 2011 1047 36
Estonia 1994 266 27
Estonia 1998 377 53
Estonia 1999 428 75
Estonia 2000 410 50
Estonia 2001 375 53
Estonia 2002 373 63
Estonia 2003 361 51
Estonia 2004 358 51
Estonia 2005 316 42
Estonia 2006 279 36
Estonia 2007 316 52
Estonia 2008 272 42
Estonia 2009 245 54
Table A1 (Continued )
Country Year Tested num Mdr  num
Estonia 2010 197 36
Estonia 2011 210 48
Estonia 2012 193 38
Finland 1997 410 0
Finland 1999 371 0
Finland 2000 374 1
Finland 2001 348 3
Finland 2002 325 3
Finland 2003 271 2
Finland 2004 200 0
Finland 2005 198 2
Finland 2006 250 1
Finland 2007 216 2
Finland 2008 238 1
Finland 2009 295 6
Finland 2010 184 4
Finland 2011 237 5
Finland 2012 206 3
France 1996 1491 8
France 1997 787 0
France 1999 910 6
France 2000 947 8
France 2001 1056 10
France 2002 1255 11
France 2003 1485 13
France 2004 1431 14
France 2005 1291 14
France 2006 1368 19
France 2007 1255 12
France 2008 1313 16
France 2009 2890 13
French Polynesia 2009 42 0
French Polynesia 2011 47 0
French Polynesia 2012 30 0
Georgia 2006 799 54
Georgia 2009 1777 183
Georgia 2010 1987 188
Georgia 2011 2197 239
Georgia 2012 1931 177
Germany 1997 1556 8
Germany 1998 1515 15
Germany 1999 1930 16
Germany 2000 1561 12
Germany 2001 2354 43
Germany 2002 3013 43
Germany 2003 3041 35
Germany 2004 3194 46
Germany 2005 3094 57
Germany 2006 3258 65
Germany 2007 2998 44
Germany 2008 2360 16
Germany 2009 2343 39
Germany 2010 2215 29
Germany 2011 2382 28
Germany 2012 2198 32
Greece 2006 507 13
Greece 2007 488 13
Greece 2009 140 9
Greece 2010 115 1
Guam 2004 29 0
Guam 2005 39 1
Guam 2006 34 1
Guam 2007 38 0
Guam 2008 37 0
Guam 2009 50 1
Guam 2010 56 2
Guam 2011 43 0
Guam 2012 31 0
Hungary 2009 486 16
Hungary 2010 474 10
Iceland 1999 7 0
Iceland 2000 8 0
Iceland 2001 11 0
Iceland 2002 6 0
Iceland 2003 4 1
Iceland 2004 7 0
Iceland 2005 7 0
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Table  A1 (Continued )
Country Year Tested num Mdr  num
Iceland 2006 12 0
Iceland 2007 10 0
Iceland 2008 5 1
Iceland 2009 6 0
Iceland 2010 19 0
Iceland 2011 4 0
Iceland 2012 4 0
Ireland 1999 101 1
Ireland 2000 136 1
Ireland 2001 67 0
Ireland 2002 186 0
Ireland 2003 191 1
Ireland 2004 197 2
Ireland 2005 200 1
Ireland 2006 145 2
Ireland 2007 127 3
Ireland 2009 162 0
Ireland 2010 200 2
Ireland 2011 176 0
Ireland 2012 190 2
Israel 1999 346 18
Israel 2000 404 37
Israel 2001 360 19
Israel 2002 348 13
Israel 2003 344 15
Israel 2004 312 11
Israel 2005 259 14
Israel 2006 241 18
Israel 2007 278 12
Israel 2008 226 12
Israel 2009 258 4
Israel 2010 245 12
Israel 2011 275 10
Israel 2012 318 15
Italy 1999 683 8
Italy 2000 688 8
Italy 2001 746 7
Italy 2002 196 12
Italy 2003 390 11
Italy 2004 510 6
Italy 2005 485 8
Italy 2006 847 28
Italy 2007 653 16
Italy 2009 1051 34
Italy 2010 836 23
Italy 2011 760 30
Japan 1997 1374 12
Japan 2002 2705 19
Jordan 2004 111 6
Jordan 2009 95 6
Kazakhstan 2001 359 51
Kazakhstan 2011 5293 1604
Kazakhstan 2012 8154 1864
Kuwait 2009 427 9
Kuwait 2010 437 5
Kuwait 2011 282 0
Latvia 1996 347 50
Latvia 1998 789 71
Latvia 1999 825 86
Latvia 2000 897 83
Latvia 2001 911 99
Latvia 2002 953 91
Latvia 2003 965 80
Latvia 2004 895 114
Latvia 2005 873 94
Latvia 2006 796 85
Latvia 2007 810 58
Latvia 2008 684 83
Latvia 2009 618 83
Latvia 2010 613 63
Latvia 2011 562 71
Latvia 2012 666 74
Lithuania 1999 819 64
Lithuania 2000 701 61
Lithuania 2001 972 75
Lithuania 2002 925 84
Lithuania 2003 955 86
Table A1 (Continued )
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Lithuania 2004 1128 104
Lithuania 2005 1293 127
Lithuania 2006 1346 128
Lithuania 2007 1257 126
Lithuania 2008 1259 113
Lithuania 2009 1074 114
Lithuania 2010 959 121
Lithuania 2011 1031 114
Lithuania 2012 1017 116
Luxembourg 2000 39 0
Luxembourg 2001 28 0
Luxembourg 2002 31 0
Luxembourg 2003 53 1
Luxembourg 2004 31 1
Luxembourg 2005 36 0
Luxembourg 2006 33 0
Luxembourg 2009 27 0
Luxembourg 2011 7 0
Malta 1999 13 0
Malta 2001 9 0
Malta 2002 13 0
Malta 2003 9 0
Malta 2004 7 0
Malta 2005 11 0
Malta 2006 14 2
Malta 2007 18 1
Malta 2009 17 0
Malta 2011 17 0
Malta 2012 13 0
Marshall Islands 2010 68 1
Marshall Islands 2011 50 1
Marshall Islands 2012 73 3
Mauritius 2010 105 1
Mauritius 2011 100 1
Mauritius 2012 121 0
Mongolia 1999 405 4
Mongolia 2007 650 9
Montenegro 2005 82 0
Montenegro 2006 90 0
Montenegro 2007 76 0
Montenegro 2008 75 0
Montenegro 2009 80 0
Montenegro 2010 61 0
Montenegro 2011 57 1
Montenegro 2012 58 0
Mozambique 1999 1028 36
Mozambique 2007 1102 39
Myanmar 2003 733 29
Myanmar 2008 1071 45
Nepal 1996 787 9
Nepal 1999 668 25
Nepal 2001 755 10
Nepal 2007 766 22
Nepal 2011 664 15
Netherlands 1996 1042 6
Netherlands 1999 899 4
Netherlands 2000 768 7
Netherlands 2001 484 2
Netherlands 2002 636 2
Netherlands 2003 518 6
Netherlands 2004 636 1
Netherlands 2005 709 5
Netherlands 2006 645 3
Netherlands 2007 553 3
Netherlands 2008 696 11
Netherlands 2009 720 16
Netherlands 2010 741 10
Netherlands 2011 695 12
Netherlands 2012 628 10
New Zealand 1995 144 2
New Zealand 1996 136 0
New Zealand 1997 123 1
New Zealand 1998 155 2
New Zealand 1999 228 2
New Zealand 2000 231 1
New Zealand 2001 272 0
New Zealand 2002 263 3
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New Zealand 2003 304 1
New Zealand 2004 278 2
New Zealand 2005 247 1
New Zealand 2006 250 1
New Zealand 2007 214 0
New Zealand 2008 231 0
New Zealand 2009 236 6
Nicaragua 1998 564 7
Nicaragua 2006 320 2
Northern Mariana
Islands
2002 29 0
Northern Mariana
Islands
2003 27 1
Northern Mariana
Islands
2004 21 1
Northern Mariana
Islands
2005 24 2
Northern Mariana
Islands
2006 18 2
Northern Mariana
Islands
2007 14 0
Northern Mariana
Islands
2009 21 0
Northern Mariana
Islands
2010 17 0
Northern Mariana
Islands
2011 19 0
Northern Mariana
Islands
2012 15 0
Norway 1996 138 3
Norway 1999 144 3
Norway 2000 160 3
Norway 2001 182 2
Norway 2002 181 7
Norway 2003 219 0
Norway 2004 223 4
Norway 2005 193 3
Norway 2006 216 1
Norway 2007 225 2
Norway 2008 180 1
Norway 2009 210 8
Norway 2010 139 4
Norway 2011 229 3
Oman 1999 133 1
Oman 2000 173 6
Oman 2001 171 0
Oman 2002 169 2
Oman 2003 153 3
Oman 2004 157 0
Oman 2005 125 0
Oman 2006 150 2
Oman 2007 145 3
Oman 2009 248 4
Oman 2010 185 0
Oman 2011 219 4
Oman 2012 248 6
Palau 2010 11 0
Palau 2011 8 1
Palau 2012 3 0
Paraguay 2001 235 5
Paraguay 2008 319 1
Peru 1996 1500 37
Peru 1999 1879 57
Peru 2006 1809 95
Peru 2012 14484 564
Poland 1997 2976 18
Poland 2001 3037 35
Poland 2004 2716 8
Poland 2008 3758 18
Poland 2011 4416 23
Poland 2012 4073 20
Portugal 1995 815 14
Portugal 2000 860 20
Portugal 2001 999 17
Portugal 2002 1404 25
Portugal 2003 1203 12
Portugal 2004 1099 12
Table A1 (Continued )
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Portugal 2005 1407 12
Portugal 2006 1120 14
Portugal 2007 1446 21
Portugal 2008 1496 19
Portugal 2009 1391 13
Portugal 2010 982 12
Portugal 2011 1155 17
Puerto Rico 2006 97 1
Puerto Rico 2007 85 2
Puerto Rico 2008 89 1
Puerto Rico 2009 54 0
Puerto Rico 2010 69 0
Puerto Rico 2011 44 3
Puerto Rico 2012 52 0
Qatar 2000 279 2
Qatar 2001 284 1
Qatar 2009 322 3
Qatar 2010 324 4
Republic of Korea 1999 2370 52
Republic of Korea 2003 1348 32
Republic of Korea 2004 2636 71
Republic of Moldova 2006 825 160
Republic of Moldova 2011 1379 359
Republic of Moldova 2012 1264 299
Romania 1995 1636 45
Romania 2004 849 24
Russian Federation -
Adygea Republic
2010 154 6
Russian Federation -
Adygea Republic
2011 123 3
Russian Federation -
Arkhangelsk Oblast
2002 301 56
Russian Federation -
Arkhangelsk Oblast
2003 299 59
Russian Federation -
Arkhangelsk Oblast
2004 316 69
Russian Federation -
Arkhangelsk Oblast
2005 297 85
Russian Federation -
Arkhangelsk Oblast
2008 290 69
Russian Federation -
Arkhangelsk Oblast
2009 292 75
Russian Federation -
Arkhangelsk Oblast
2010 316 111
Russian Federation -
Arkhangelsk Oblast
2011 321 94
Russian Federation -
Belgorod Oblast
2008 442 85
Russian Federation -
Belgorod Oblast
2009 359 71
Russian Federation -
Belgorod Oblast
2010 342 52
Russian Federation -
Belgorod Oblast
2011 308 57
Russian Federation -
Bryansk Oblast
2008 549 71
Russian Federation -
Bryansk Oblast
2009 562 73
Russian Federation -
Bryansk Oblast
2010 447 59
Russian Federation -
Bryansk Oblast
2011 409 54
Russian Federation -
Chukotka
Autonomous Okrug
2010 35 3
Russian Federation -
Chukotka
Autonomous Okrug
2011 49 3
Russian Federation -
Chuvasia Republic
2008 613 87
Russian Federation -
Chuvasia Republic
2009 579 88
Russian Federation -
Chuvasia Republic
2010 503 78
Russian Federation -
Chuvasia Republic
2011 550 108
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Russian Federation -
Ivanovo Oblast
1996 248 10
Russian Federation -
Ivanovo Oblast
1998 222 20
Russian Federation -
Ivanovo Oblast
2002 350 43
Russian Federation -
Ivanovo Oblast
2008 275 55
Russian Federation -
Ivanovo Oblast
2009 276 56
Russian Federation -
Ivanovo Oblast
2010 238 54
Russian Federation -
Ivanovo Oblast
2011 268 48
Russian Federation -
Kaliningrad oblast
2006 521 151
Russian Federation -
Kaliningrad Oblast
2008 436 84
Russian Federation -
Kaliningrad Oblast
2009 354 79
Russian Federation -
Kaliningrad Oblast
2010 326 78
Russian Federation -
Kaliningrad Oblast
2011 295 67
Russian Federation -
Kamchatka Krai
Oblast
2010 57 11
Russian Federation -
Kamchatka Krai
Oblast
2011 90 23
Russian Federation -
Karelia Republic
2009 195 48
Russian Federation -
Karelia Republic
2010 185 51
Russian Federation -
Karelia Republic
2011 151 53
Russian Federation -
Kemerovo Oblast
2008 1565 280
Russian Federation -
Kemerovo Oblast
2009 1661 377
Russian Federation -
Kemerovo Oblast
2010 1614 339
Russian Federation -
Kemerovo Oblast
2011 1491 327
Russian Federation -
Khabarovsk Krai
2010 684 160
Russian Federation -
Khabarovsk Krai
2011 636 168
Russian Federation -
Khakassia Republic
2010 233 63
Russian Federation -
Khakassia Republic
2011 249 67
Russian Federation -
Komi Republic
2008 305 79
Russian Federation -
Komi Republic
2009 318 61
Russian Federation -
Komi Republic
2010 277 54
Russian Federation -
Komi Republic
2011 236 56
Russian Federation -
Kostroma Oblast
2008 119 8
Russian Federation -
Kostroma Oblast
2010 112 17
Russian Federation -
Kostroma Oblast
2011 102 17
Russian Federation -
Leningrad Oblast
2010 378 101
Russian Federation -
Leningrad Oblast
2011 335 121
Russian Federation -
Mary El Republic
2006 304 38
Russian Federation -
Mary El Republic
2008 267 43
Russian Federation -
Mary El Republic
2009 365 57
Table A1 (Continued )
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Russian Federation -
Mary El Republic
2010 330 67
Russian Federation -
Mary-El Republic
2011 330 60
Russian Federation -
Murmansk Oblast
2008 173 49
Russian Federation -
Murmansk Oblast
2009 190 55
Russian Federation -
Murmansk Oblast
2010 173 36
Russian Federation -
Murmansk Oblast
2011 164 54
Russian Federation -
Nizhni Novgorod
Oblast
2010 798 186
Russian Federation -
Nizhni Novgorod
Oblast
2011 598 178
Russian Federation -
Novgorod Oblast
2008 152 30
Russian Federation -
Novgorod Oblast
2009 139 29
Russian Federation -
Novgorod Oblast
2010 156 42
Russian Federation -
Novgorod Oblast
2011 147 34
Russian Federation -
Orel Oblast
2002 379 10
Russian Federation -
Orel Oblast
2003 330 11
Russian Federation -
Orel Oblast
2004 328 19
Russian Federation -
Orel Oblast
2005 311 23
Russian Federation -
Orel Oblast
2006 317 28
Russian Federation -
Orel Oblast
2008 296 16
Russian Federation -
Orel Oblast
2009 254 16
Russian Federation -
Orel Oblast
2010 241 21
Russian Federation -
Orel Oblast
2011 196 15
Russian Federation -
Penza Oblast
2008 457 33
Russian Federation -
Penza Oblast
2009 532 66
Russian Federation -
Penza Oblast
2010 425 91
Russian Federation -
Penza Oblast
2011 375 81
Russian Federation -
Primorsky Krai
2010 1011 210
Russian Federation -
Primorsky Krai
2011 825 168
Russian Federation -
Pskov oblast
2006 343 55
Russian Federation -
Pskov Oblast
2008 370 101
Russian Federation -
Pskov Oblast
2009 302 75
Russian Federation -
Pskov Oblast
2010 312 87
Russian Federation -
Pskov Oblast
2011 279 54
Russian Federation -
Sakha (Yakutia)
Republic
2010 245 83
Russian Federation -
Sakha (Yakutia)
Republic
2011 303 95
Russian Federation -
Sakhalin Oblast
2010 225 53
Russian Federation -
Sakhalin Oblast
2011 242 35
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Russian Federation -
Samara Oblast
2010 939 235
Russian Federation -
Samara Oblast
2011 960 304
Russian Federation -
Tambov Oblast
2008 307 26
Russian Federation -
Tambov Oblast
2009 343 60
Russian Federation -
Tambov Oblast
2010 312 53
Russian Federation -
Tambov Oblast
2011 309 53
Russian Federation -
Tomsk Oblast
1999 417 27
Russian Federation -
Tomsk Oblast
2000 561 48
Russian Federation -
Tomsk Oblast
2001 532 57
Russian Federation -
Tomsk Oblast
2002 533 73
Russian Federation -
Tomsk Oblast
2003 527 59
Russian Federation -
Tomsk Oblast
2004 565 95
Russian Federation -
Tomsk Oblast
2005 515 77
Russian Federation -
Tomsk Oblast
2008 424 55
Russian Federation -
Tomsk Oblast
2009 439 79
Russian Federation -
Tomsk Oblast
2010 390 69
Russian Federation -
Tomsk Oblast
2011 351 74
Russian Federation -
Tula Oblast
2008 489 58
Russian Federation -
Tula Oblast
2009 454 64
Russian Federation -
Tula Oblast
2010 417 55
Russian Federation -
Tula Oblast
2011 377 33
Russian Federation -
Ulyanovsk Oblast
2010 265 80
Russian Federation -
Ulyanovsk Oblast
2011 280 75
Russian Federation -
Vladimir Oblast
2008 422 59
Russian Federation -
Vladimir Oblast
2009 421 88
Russian Federation -
Vladimir Oblast
2010 400 78
Russian Federation -
Vladimir Oblast
2011 377 77
Russian Federation -
Vologda Oblast
2009 214 21
Russian Federation -
Vologda Oblast
2010 240 49
Russian Federation -
Vologda Oblast
2011 176 41
Russian Federation -
Voronezh Oblast
2008 597 87
Russian Federation -
Voronezh Oblast
2009 534 78
Russian Federation -
Voronezh Oblast
2010 461 89
Russian Federation -
Voronezh Oblast
2011 394 108
Serbia 2005 1112 4
Serbia 2006 990 0
Serbia 2007 1130 7
Serbia 2008 923 6
Serbia 2010 811 4
Serbia 2011 863 3
Serbia 2012 716 6
Sierra Leone 1996 463 5
Sierra Leone 1997 117 1
Table A1 (Continued )
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Singapore 1996 980 3
Singapore 2001 823 4
Singapore 2002 785 2
Singapore 2003 862 1
Singapore 2004 838 2
Singapore 2005 895 2
Singapore 2006 861 3
Singapore 2007 827 3
Singapore 2008 919 1
Singapore 2009 915 3
Singapore 2010 923 2
Singapore 2011 952 6
Singapore 2012 1178 19
Slovakia 1998 589 2
Slovakia 1999 456 3
Slovakia 2000 465 5
Slovakia 2001 464 1
Slovakia 2002 407 2
Slovakia 2003 350 4
Slovakia 2004 292 1
Slovakia 2005 248 4
Slovakia 2006 340 3
Slovakia 2007 343 3
Slovakia 2009 191 0
Slovakia 2010 185 0
Slovakia 2011 147 2
Slovakia 2012 142 0
Slovenia 1997 290 2
Slovenia 1999 304 0
Slovenia 2000 282 0
Slovenia 2001 281 3
Slovenia 2002 262 1
Slovenia 2003 226 1
Slovenia 2004 202 0
Slovenia 2005 217 0
Slovenia 2006 176 1
Slovenia 2007 174 0
Slovenia 2008 182 1
Slovenia 2009 167 1
Slovenia 2010 123 0
Slovenia 2011 171 0
Slovenia 2012 114 0
South Africa -
Mpumalanga
Province
1997 661 10
South Africa -
Mpumalanga
Province
2002 702 18
Spain - Barcelona 1996 218 1
Spain - Barcelona 1998 315 1
Spain - Barcelona 1999 128 0
Spain - Barcelona 2000 135 3
Spain - Barcelona 2001 133 1
Swaziland 1995 334 3
Swaziland 2009 352 27
Sweden 1997 356 2
Sweden 1999 377 3
Sweden 2000 322 4
Sweden 2001 338 2
Sweden 2002 319 4
Sweden 2003 322 6
Sweden 2004 347 5
Sweden 2005 425 2
Sweden 2006 377 2
Sweden 2007 346 12
Sweden 2008 349 7
Sweden 2009 424 8
Sweden 2010 288 9
Sweden 2011 375 9
Sweden 2012 453 11
Switzerland 1997 322 0
Switzerland 1999 428 3
Switzerland 2000 330 0
Switzerland 2001 342 3
Switzerland 2002 368 3
Switzerland 2003 336 8
Switzerland 2004 340 3
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Switzerland 2005 326 2
Switzerland 2006 382 4
Switzerland 2007 264 5
Switzerland 2008 258 3
Switzerland 2009 269 0
Switzerland 2010 270 1
Switzerland 2011 304 1
Switzerland 2012 246 3
Thailand 1997 1137 24
Thailand 2001 1505 14
Thailand 2006 1150 19
The  Former Yugoslav
Republic of
Macedonia
2009 191 0
The  Former Yugoslav
Republic of
Macedonia
2010 153 2
The  Former Yugoslav
Republic of
Macedonia
2011 130 0
The  Former Yugoslav
Republic of
Macedonia
2012 155 0
United Kingdom 1995 2742 29
United Kingdom 1997 3053 24
United Kingdom 1999 2138 10
United Kingdom 2000 2312 21
United Kingdom 2001 2752 23
United Kingdom 2002 3110 22
United Kingdom 2003 2919 28
United Kingdom 2004 3105 22
United Kingdom 2005 3428 23
United Kingdom 2006 4677 39
United Kingdom 2007 3441 34
United Kingdom 2008 3749 38
United Kingdom 2009 3957 37
United Kingdom 2011 4549 61
United States of
America
1993 16601 407
United States of
America
1994 16415 353
United States of
America
1995 16022 254
United States of
America
1996 15358 207
United States of
America
1997 14448 155
United States of
America
1998 13420 132
United States of
America
1999 12655 127
United States of
America
2000 11825 120
United States of
America
2001 11510 115
United States of
America
2002 10813 132
United States of
America
2003 10751 95
United States of
America
2004 10481 100
United States of
America
2005 10064 98
United States of
America
2006 9901 102
United States of
America
2007 9642 104
United States of
America
2008 9296 86
United States of
America
2009 8196 94
United States of
America
2010 7593 90
United States of
America
2011 6899 94
United States of
America
2012 6790 70
Table A1 (Continued )
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Uruguay 1997 484 0
Uruguay 1999 315 1
Uruguay 2005 335 0
Uruguay 2011 422 1
Uruguay 2012 466 0
Viet  Nam 1997 640 15
Viet  Nam 2006 1619 44
Yemen 2004 510 15
Yemen 2011 1108 19
Zambia 2000 445 8
Zambia 2008 604 2
Data on the Russian Federation are obtained from the annual report: Tuberculosis
in  the Russian Federation: an analytical review of statistical indicators used in the
Russian Federation and in the world (in Russian). Moscow: Ministry of Health of the
Russian Federation et al.
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Fig. A2. Patterns of notiﬁed TB and estimated MDR-TB among notiﬁed cases in Peru
and South Korea. The black solid markers and associated conﬁdence intervals show
MDR-TB data from surveillance while the gray solid markers and associated con-
ﬁdence intervals show MDR-TB data from surveys. The open circles show new TB
notiﬁcation data.
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